经与会监事认真审议，本次会议以现场表决方式通过如下决议： （一）审议并通过《关于修订〈公司章程〉并调整公司治理结构的议案》 根据《公司法》《上市公司章程指引》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所创业板上市公司自律监管指引第 2 号——规范运作》等最新法 律法规、规范性文件的规定，为进一步规范公司运作机制，提升公司治理水平， 结合公司实际情况，公司拟不再设监事会和监事，由公司董事会审计委员会行使 《公司法》规定的监事会职权，《公司监事会议事规则》相应废止，公司监事会 主席欧阳柏伸、监事陈春耕、职工代表监事黄绍波在监事会中担任的职务将自然 免除，《公司章程》中相关条款亦作出相应修订。 | 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-090 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 第五届监事会第十七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 三诺生物传感股份有限公司（以下简称"公司"）第五届监事 ...

本次会议采用现场和通讯表决方式进行表决，经与会董事认真审议，本次会 议形成以下决议： | 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-089 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 第五届董事会第二十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 三诺生物传感股份有限公司（以下简称"公司"）第五届董事会第二十二次 会议于 2025 年 12 月 15 日（星期一）上午 10 时在公司会议室以现场结合通讯方 式召开。本次会议的通知已于 2025 年 12 月 12 日通过书面或电子邮件方式送达 全体董事。应出席本次会议的董事 7 人，实际出席本次会议的董事 7 人，分别为 李少波先生（兼任总经理）、李心一女士、车宏菁女士、李晖（LI HUI）先生、 袁洪先生、康熙雄先生、陈纪正女士。本次会议由董事长李少波先生召集并主持， 公司监事、高级管理人员列席了会议。会议的召集、召开符合《公司法》及《公 司章程》《公司董事 ...

| 证券代码：300298 | 证券简称：三诺生物 公告编号：2025-087 | | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | 三诺生物传感股份有限公司 关于控股股东部分股份补充质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 三诺生物传感股份有限公司（以下简称"公司"）于近日接到公司控股股东、 实际控制人李少波先生的通知，获悉其所持有本公司的部分股份办理了补充质押 业务，现将有关情况说明如下： 一、股东股份补充质押的基本情况 | 股东 名称 | 是否为控股 股东或第一 大股东及其 | 本次质押 股份数量 | 占其所持 股份比例 | 占公司总 股本比例 | 是否为限售股 （如是，注明限 | 是否 为补 充质 | 质押起始日 | | 质押到期日 | | 质权人 | 质押 用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 一致行动人 | （股） | | | 售类型） | 押 | | | | ...

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-088 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 关于三诺转债2025年付息的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、"三诺转债"（债券代码：123090）将于2025年12月22日按面值支付第 五年利息，每10张"三诺转债"（面值1,000元）利息为18.00元（含税）。 2、债权登记日：2025年12月19日（星期五） 3、付息日：2025年12月22日（星期一） 4、除息日：2025年12月22日（星期一） 5、本次付息期间及票面利率：计息期间为2024年12月21日至2025年12月20 日，票面利率为1.80%。 6、"三诺转债"本次付息的债权登记日为2025年12月19日，截至2025年12 月19日下午深圳证券交易所收市后，在中国证券登记结算有限责任公司深圳分 公司（以下简称"中国结算深圳分公司"）登记在册的"三诺转债"持有人享 有本次派发的利息，在202 ...

Group 1 - Huawei officially launched the AI data platform for the medical field on December 7, which is built on the OceanStor A800 storage and includes three core technologies: knowledge generation and retrieval, memory extraction and recall, and UCM inference acceleration [1] - The successful implementation of Huawei's AI data platform at West China Hospital exemplifies the empowerment of AI technology in the medical sector, addressing the long-standing "triangle constraint" of cost, quality, and accessibility [1] - The Chinese AI medical industry is projected to reach a market size of 115.7 billion yuan by 2025 and is expected to grow to 159.8 billion yuan by 2028, with a compound annual growth rate of 10.5% from 2022 to 2028 [1] Group 2 - The AI medical imaging and AI pharmaceutical sectors are experiencing rapid growth, with the AI medical imaging market expected to exceed 15 billion yuan by 2025 and reach 23.57 billion yuan by 2026 [2] - The AI pharmaceutical market is projected to grow from 730 million yuan in 2024 to 5.86 billion yuan by 2028, with a compound annual growth rate of 68.5% [2] - There are currently 33 concept stocks in the A-share market related to AI medical, with 10 companies disclosing collaborations with Huawei in AI medical applications, including RunDa Medical, Weining Health, and Dian Diagnostics [2] Group 3 - United Imaging Healthcare stated that all its imaging diagnostic equipment has been empowered by AI platforms, enhancing various aspects such as hardware, software, applications, and workflows [3] - Among the 14 AI medical concept stocks that received significant institutional attention, 13 are expected to see profit growth by 2025, with companies like Hongbo Pharmaceutical, Dian Diagnostics, and Weining Health projected to have profit increases exceeding 100% or to turn profitable [3]

证券日报网讯12月8日，三诺生物（300298）在互动平台回答投资者提问时表示，公司将积极拓展境内 外业务布局。 ...

Core Viewpoint - The pharmaceutical and biotechnology market currently lacks a clear main theme, but the release of the first "Medical Insurance + Commercial Insurance Dual Directory" by the National Healthcare Security Administration on December 7 may boost investment enthusiasm for innovative drugs [1] Market Performance - Last week, the pharmaceutical and biotechnology sector had a return of -0.74%, underperforming the CSI 300 by 2.02%, ranking 21st among 31 primary sub-industry indices [2] - The pharmaceutical commercial sub-sector had the highest weekly return at 5.19%, outperforming the CSI 300 by 3.91%, while the medical services sub-sector ranked sixth with a return of -1.37%, underperforming the CSI 300 by 2.65% [2] Innovative Drugs - Companies recommended for investment in innovative drugs include: - Innovent Biologics - 3SBio - Hengrui Medicine - Kelun-Biotech - Baillie Gifford - Rongchang Biologics - Yimeng Biologics - Huyou Pharmaceutical - King’s Ray Biotech - Valiant Biotech - Lee's Pharmaceutical [2] CXO and Life Sciences Upstream Industry Chain - Recommended global CXO leaders include: - WuXi AppTec - WuXi Biologics - WuXi AppTec's subsidiary - Kanglong Chemical - Kailai Ying [3] - Recommended domestic clinical CRO leaders include: - Tigermed - Proprius - Nossg - Sunshine Nuohe [3] - Recommended resource-type CXOs include: - Zhaoyan New Drug - Yinos - Medicy - Baiaosaitu - Yaokang Biotech [3] - Recommended companies in the life sciences upstream industry chain include: - Baipusais - Haoyuan Pharmaceutical - Bid Pharmaceutical - Nami Technology - Aopumai - Haier Biomedical - Aladdin - Titan Technology [3] Companies with Improved Operations and High Dividends - Companies recommended for attention include: - Baiyunshan - Sinopharm [4] High-end Medical Equipment - Recommended companies benefiting from overseas pharmaceutical investments include: - Sensong International - Dongfulong - Chutian Technology [4] - Companies expected to see business growth from hospital procurement recovery include: - United Imaging - Kaili Medical - Xinhua Medical - Mindray Medical - Aohua Endoscopy - Mountain Outside Mountain [4] - Companies with domestic demand-driven medical device recovery include: - Yiyue Medical - Kefu Medical - Sanofi Biotech [4] - Companies with restored overseas orders include: - Meihua Medical - Haitai New Light - Ruimaite [4] - Companies with increasing market penetration in high-end medical consumables include: - Xinmai Medical - Micron Medical - Weigao - Micron Brain Science - Aikang Medical - Chunli Medical [4]

Core Insights - SINOCARE has successfully established a presence in the African market, exporting an average of 40,000 blood glucose monitoring devices and 40,000 boxes of test strips monthly, covering over 40 countries including Egypt, Nigeria, and Kenya [2] - The company began its expansion into Africa around 2017, facing initial challenges due to negative perceptions of Chinese products and strong competition from established Western brands [2][3] - SINOCARE's strategy focuses on product quality and affordability, exemplified by its blood glucose meter achieving a low error rate of ±3%, which helped it gain entry into the Algerian market [3] Market Dynamics - The demand for diabetes monitoring in Africa is increasing, with the World Health Organization predicting that there will be 60 million diabetes patients in sub-Saharan Africa by 2050, reflecting a compound annual growth rate of over 140% [4] - The company is set to launch its AI-driven "Aikan" series of Continuous Glucose Monitoring (CGM) products in Africa in 2024, which will allow users to monitor their blood glucose levels continuously via a connected app [3] - Challenges such as weak local infrastructure are being addressed by SINOCARE through offline storage and scheduled data uploads [4] Competitive Landscape - The acceptance of Chinese products in Africa is gradually improving, with increasing competition from other Chinese companies entering the market, which poses challenges for SINOCARE [4]

Core Viewpoint - SINOCARE has successfully penetrated the African market, exporting an average of 40,000 blood glucose monitoring devices and test strips monthly, covering over 40 countries including Egypt, Nigeria, and Kenya [3][4]. Group 1: Market Entry and Challenges - SINOCARE began its expansion into the African market around 2017, facing initial challenges due to negative perceptions of Chinese products and strong competition from established Western brands [3][4]. - The company aims to win over local markets by offering high-quality products at affordable prices, addressing the need for reliable diabetes management tools [4][5]. Group 2: Product Development and Innovation - SINOCARE's blood glucose meters have achieved a low error rate of ±3%, which helped secure approval from the Algerian Ministry of Health, facilitating market entry [5]. - The introduction of the "Aikan" series Continuous Glucose Monitoring (CGM) products in 2024, equipped with AI algorithms, allows users to monitor blood glucose levels continuously for 15 days via a connected app [5][6]. Group 3: Market Demand and Future Outlook - The demand for diabetes testing in Africa is increasing, with the World Health Organization predicting that there will be 60 million diabetes patients in sub-Saharan Africa by 2050, reflecting a compound annual growth rate of over 140% [6]. - As acceptance of Chinese products in Africa grows, competition is intensifying, necessitating strategic adaptability from companies like SINOCARE to maintain market share [6].

Core Insights - SINOCARE has successfully established a presence in the African market, exporting an average of 40,000 blood glucose monitoring devices and 40,000 test strips monthly, covering over 40 countries including Egypt, Nigeria, and Kenya [1] - The company began its African market expansion in 2017, facing challenges due to the perception of Chinese products and strong competition from established Western brands [1][2] - SINOCARE's strategy focuses on product quality and affordability to penetrate the local market [1] Market Dynamics - In Algeria, SINOCARE's blood glucose meter received a health department report confirming an error rate below international standards (±3%), facilitating market entry [2] - The dietary habits of African residents, including high sugar consumption, complicate diabetes management and patient education [2] - The introduction of AI-driven continuous glucose monitoring (CGM) products in 2024 aims to enhance health awareness among African consumers [2] Growth Potential - The demand for diabetes detection in Africa is increasing, with an estimated 60 million diabetes patients projected by 2050 in sub-Saharan Africa, reflecting a compound annual growth rate exceeding 140% [3] - The acceptance of Chinese products in the African market is improving, leading to increased competition among Chinese companies [3]